CN119838000A - 用于药物治疗的司美鲁肽 - Google Patents

用于药物治疗的司美鲁肽 Download PDF

Info

Publication number
CN119838000A
CN119838000A CN202510084667.2A CN202510084667A CN119838000A CN 119838000 A CN119838000 A CN 119838000A CN 202510084667 A CN202510084667 A CN 202510084667A CN 119838000 A CN119838000 A CN 119838000A
Authority
CN
China
Prior art keywords
semanteme
subject
week
administered
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510084667.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·卡比施
T·汉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60083831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN119838000(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN119838000A publication Critical patent/CN119838000A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202510084667.2A 2017-10-12 2018-10-10 用于药物治疗的司美鲁肽 Pending CN119838000A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17196254.1 2017-10-12
EP17196254 2017-10-12
CN201880066425.9A CN111212657A (zh) 2017-10-12 2018-10-10 用于药物治疗的司美鲁肽
PCT/EP2018/077654 WO2019072941A1 (en) 2017-10-12 2018-10-10 SEMAGLUTIDE IN MEDICAL THERAPY

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880066425.9A Division CN111212657A (zh) 2017-10-12 2018-10-10 用于药物治疗的司美鲁肽

Publications (1)

Publication Number Publication Date
CN119838000A true CN119838000A (zh) 2025-04-18

Family

ID=60083831

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202510084667.2A Pending CN119838000A (zh) 2017-10-12 2018-10-10 用于药物治疗的司美鲁肽
CN202510086779.1A Pending CN120241968A (zh) 2017-10-12 2018-10-10 用于药物治疗的司美鲁肽
CN201880066425.9A Withdrawn CN111212657A (zh) 2017-10-12 2018-10-10 用于药物治疗的司美鲁肽
CN202411858188.3A Pending CN119950682A (zh) 2017-10-12 2018-10-10 用于药物治疗的司美鲁肽

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202510086779.1A Pending CN120241968A (zh) 2017-10-12 2018-10-10 用于药物治疗的司美鲁肽
CN201880066425.9A Withdrawn CN111212657A (zh) 2017-10-12 2018-10-10 用于药物治疗的司美鲁肽
CN202411858188.3A Pending CN119950682A (zh) 2017-10-12 2018-10-10 用于药物治疗的司美鲁肽

Country Status (18)

Country Link
US (4) US12029779B2 (enExample)
EP (1) EP3694538A1 (enExample)
JP (2) JP7148605B2 (enExample)
KR (1) KR20200069316A (enExample)
CN (4) CN119838000A (enExample)
AU (2) AU2018348929B2 (enExample)
BR (1) BR112020006246A2 (enExample)
CA (1) CA3078652A1 (enExample)
CL (1) CL2020000812A1 (enExample)
IL (3) IL322968A (enExample)
MA (1) MA50358A (enExample)
MX (3) MX2020003049A (enExample)
MY (1) MY204827A (enExample)
PH (1) PH12020550185A1 (enExample)
SG (1) SG11202002841PA (enExample)
TW (1) TWI842681B (enExample)
WO (1) WO2019072941A1 (enExample)
ZA (3) ZA202503387B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50358A (fr) * 2017-10-12 2020-08-19 Novo Nordisk As Sémaglutide en thérapie médicale
AU2021208601B2 (en) * 2020-02-18 2025-06-05 Novo Nordisk A/S Glp-1 compositions and uses thereof
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US20240197700A1 (en) * 2021-03-29 2024-06-20 Sanford Health Methods and Compositions for Treating Lysosomal Storage Disorders
AU2023285400A1 (en) * 2022-06-08 2024-12-05 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
WO2024249659A2 (en) * 2023-05-30 2024-12-05 The Medical College Of Wisconsin, Inc. Methods for weight loss and/or reducing weight gain
WO2024252134A1 (en) * 2023-06-05 2024-12-12 Closed Loop Medicine Ltd Dosing of incretin pathway drugs

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
CN102784386A (zh) 2003-11-20 2012-11-21 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
JP5175103B2 (ja) 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス 安定なペプチド製剤
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
KR101384456B1 (ko) 2005-09-14 2014-04-10 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
MX2008013216A (es) 2006-04-14 2008-10-27 Mannkind Corp Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1).
EP2121897A4 (en) 2007-03-20 2010-03-31 Nippon Kayaku Kk METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL
EP2190873B1 (en) 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
LT2373681T (lt) 2008-12-10 2017-04-10 Glaxosmithkline Llc Albiglutido farmacinės kompozicijos
NZ594044A (en) 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
JP2013514322A (ja) 2009-12-16 2013-04-25 ノヴォ ノルディスク アー／エス 修飾されたｎ末端を有するｇｌｐ−１受容体アゴニスト化合物
KR101819609B1 (ko) 2010-05-05 2018-01-17 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
PL3326620T3 (pl) 2010-12-16 2020-08-24 Novo Nordisk A/S Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego
AR084558A1 (es) 2010-12-22 2013-05-22 Marcadia Biotech Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
JP2014520159A (ja) 2011-06-24 2014-08-21 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｇｌｐ−１受容体アゴニストの徐放性製剤による糖尿病の治療方法
JP6250034B2 (ja) * 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
DK2866825T3 (da) * 2012-07-01 2020-06-08 Novo Nordisk As Anvendelse af langstidsvirkende glp-1-peptider
PT2991671T (pt) * 2013-05-02 2018-11-05 Novo Nordisk As Dosagem oral de compostos de glp-1
MY197023A (en) 2015-12-23 2023-05-22 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
EP3648762A4 (en) 2017-08-04 2021-03-24 Ovid Therapeutics, Inc. USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED DISEASES
MA50358A (fr) * 2017-10-12 2020-08-19 Novo Nordisk As Sémaglutide en thérapie médicale

Also Published As

Publication number Publication date
WO2019072941A1 (en) 2019-04-18
MX2020003049A (es) 2020-07-27
AU2025203535A1 (en) 2025-06-05
CL2020000812A1 (es) 2020-08-14
JP7475398B2 (ja) 2024-04-26
JP2022132414A (ja) 2022-09-08
JP2020536854A (ja) 2020-12-17
ZA202503388B (en) 2025-09-25
ZA202503387B (en) 2025-09-25
RU2020114960A3 (enExample) 2022-02-11
IL273470A (en) 2020-05-31
TWI842681B (zh) 2024-05-21
US12029779B2 (en) 2024-07-09
IL322969A (en) 2025-10-01
US12295988B2 (en) 2025-05-13
TW201914611A (zh) 2019-04-16
MX2025002189A (es) 2025-04-02
JP7148605B2 (ja) 2022-10-05
IL322968A (en) 2025-10-01
AU2018348929A1 (en) 2020-05-07
EP3694538A1 (en) 2020-08-19
BR112020006246A2 (pt) 2021-03-30
CN111212657A (zh) 2020-05-29
US20240316159A1 (en) 2024-09-26
ZA202503350B (en) 2025-09-25
CA3078652A1 (en) 2019-04-18
CN119950682A (zh) 2025-05-09
US20240415935A1 (en) 2024-12-19
US20200237876A1 (en) 2020-07-30
MX2025002188A (es) 2025-04-02
MA50358A (fr) 2020-08-19
AU2018348929B2 (en) 2025-02-27
MY204827A (en) 2024-09-18
CN120241968A (zh) 2025-07-04
KR20200069316A (ko) 2020-06-16
US20250235511A1 (en) 2025-07-24
SG11202002841PA (en) 2020-04-29
RU2020114960A (ru) 2021-10-28
PH12020550185A1 (en) 2021-03-01

Similar Documents

Publication Publication Date Title
CN119838000A (zh) 用于药物治疗的司美鲁肽
US20240100127A1 (en) Tirzepatide therapeutic methods
Huang et al. Helicobacter pylori infection decreases metformin tolerance in patients with type 2 diabetes mellitus
Nimitphong et al. Metformin for preventing progression from prediabetes to diabetes mellitus in people living with human immunodeficiency virus
US20240277745A1 (en) Pemafibrate and/or tofogliflozin for use in treating liver disease
RU2800651C2 (ru) Семаглутид в лекарственной терапии
JP2023532622A (ja) 高尿酸血症の治療
Sharma et al. Comparative study of efficacy and safety of sitagliptin versus glimepiride in patients of type-2 diabetes mellitus inadequately controlled with metformin alone
Wulandari et al. Antidiabetic Regimen and Factors Associated with Glycemic Control in Patients with Type 2 Diabetes mellitus in Public Health Centers in Jakarta: A Cross-Sectional Study
US20210100872A1 (en) Pharmacological Formulation Comprising Cyclo (HIS-PRO) As Effective Ingredient For Preventing Or Treating Diabetes Mellitus
EP4656198A2 (en) Use of gmi from ganoderma lucidum spores in the preparation of pharmaceuticals and food products
BR122024015864A2 (pt) Uso de semaglutida para preparação de uma composição farmacêutica para controle de peso
BR122025013280A2 (pt) Uso de semaglutida para fabricar uma solução injetável subcutânea para tratar diabetes tipo 2
BR122024015868A2 (pt) Uso de semaglutida para preparação de uma composição farmacêutica para tratamento e/ou prevenção de obesidade e/ou de sobrepeso
Maree et al. Health Status of Diabetic Patients in the Eastern Region of Libya
Arya et al. Study of Efficacy and Safety of Pioglitazone in Combination with Metformin in Patients with Type-2 Diabetes Mellitus.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination